Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06189170
EARLY_PHASE1

Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

Sponsor: Kariya Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.

Official title: A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2024-08-01

Completion Date

2026-03-31

Last Updated

2025-03-07

Healthy Volunteers

Yes

Interventions

DRUG

KP405

Experimental drug

DRUG

Placebo

Placebo

Locations (1)

MAC

Manchester, United Kingdom